Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation

Infection

Volumn 42, Issue 4, 2014, Pages 639-647

  Yoshikawa, K ^a   Nakazawa, Y ^a   Katsuyama, Y ^b   Hirabayashi, K ^a   Saito, S ^a   Shigemura, T ^a   Tanaka, M ^a   Yanagisawa, R ^a   Sakashita, K ^a   Koike, K ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Invasive fungal infection; Micafungin; Prophylaxis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; MICAFUNGIN; TACROLIMUS; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HUMAN; INFANT; INFUSION RELATED REACTION; LIVER DYSFUNCTION; MALE; ADVERSE DRUG REACTION; CHEMISTRY; CHEMOPROPHYLAXIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MYCOSES; PLASMA; PRESCHOOL CHILD;

ADOLESCENT; ANTIFUNGAL AGENTS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ECHINOCANDINS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LIPOPEPTIDES; MALE; MYCOSES; PLASMA;

EID: 84906790381     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-014-0601-9     Document Type: Article

References (25)

1. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, Gachot B, Heinz WJ, Lass-Flörl C, Ribaud P, Thiebaut A, Cordonnier C; Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant. 2011;46:709-18.
2. Dvorak CC, Fisher BT, Sung L, Steinbach WJ, Nieder M, Alexander S, Zaoutis TE. Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. Pediatr Blood Cancer. 2012;59:21-6.
3. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis. 1994;19:684-6. (Pubitemid 24301143)
4. Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin a in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12:325-34. (Pubitemid 43273718)
5. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2009;44:371-4.
6. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-15. (Pubitemid 34851833)
7. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist. 2000;5:120-35. (Pubitemid 30238232)
8. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, Goto T, Tomishima M, Ohki H, Yamada A, Kawabata K, Takasugi H, Sakane K, Tanaka H, Matsumoto F, Kuwahara S. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 2000;44:57-62. (Pubitemid 30010672)
9. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-16. (Pubitemid 39518200)
10. Yanagisawa R, Katsuyama Y, Shigemura T, Saito S, Tanaka M, Nakazawa Y, Sakashita K, Shiohara M, Koike K. Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. Bone Marrow Transplant. 2011;46:90-7.
11. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-21.
12. Yamato Y, Kaneko H, Tanimoto K, Katashima M, Ishibashi K, Kawamura A, Terakawa M, Kagayama A. Simultaneous determination of antifungal drug, micafungin, and its two active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Jpn J Chemother. 2002;50:68-73. (Pubitemid 36033011)
13. Castagnola E, Faraci M, Moroni C, Bandettini R, Granata C, Caruso S, Bagnasco F, Caviglia I, Malgorzata M, Furfaro E, Natalizia AR, de Fazio V, Morreale G, Lanino E, Haupt R, Dini G, Viscoli C. Invasive mycoses in children receiving hemopoietic SCT. Bone Marrow Transplant. 2008;41:S107-11. (Pubitemid 351864720)
14. Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2005;36:621-9. (Pubitemid 43115019)
15. Barker JN, Hough RE, van Burik JA, DeFor TE, MacMillan ML, O'Brien MR, Wagner JE. Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source. Biol Blood Marrow Transplant. 2005;11:362-70. (Pubitemid 40542929)
16. Benjamin DK Jr, Miller WC, Bayliff S, Martel L, Alexander KA, Martin PL. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J. 2002;21:227-34. (Pubitemid 34214140)
17. Hovi L, Saarinen-Pihkala UM, Vettenranta K, Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant. 2000;26:999-1004.
18. George B, Mathews V, Viswabandya A, Srivastava A, Chandy M. Infections in children undergoing allogeneic bone marrow transplantation in India. Pediatr Transplant. 2006;10:48-54.
19. Shimoeda S, Ohta S, Kobayashi H, Yamato S, Sasaki M, Kawano K. Effective blood concentration of micafungin for pulmonary aspergillosis. Biol Pharm Bull. 2006;29:1886-91. (Pubitemid 44338412)
20. Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol. 2005;45:1145-52. (Pubitemid 41361914)
21. Nakagawa Y, Ichii Y, Saeki Y, Kodaka M, Suzuki K, Kishino S. Plasma concentration of micafungin in patients with hematologic malignancies. J Infect Chemother. 2007;13:39-45. (Pubitemid 46356242)
22. Muraki Y, Iwamoto T, Kagawa Y, Sakurai H, Usui M, Isaji S, Uemoto S, Okuda M. The impact of total bilirubin on plasma micafungin levels in living-donor liver transplantation recipients with severe liver dysfunction. Biol Pharm Bull. 2009;32:750-4.
23. Bormann AM, Morrison VA. Review of the pharmacology and clinical studies of micafungin. Drug Des Devel Ther. 2009;3:295-302.
24. Fukuoka N, Imataki O, Ohnishi H, Kitanaka A, Kubota Y, Ishida T, Tanaka T. Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. Transplant Proc. 2010;42:2725-30.
25. Kusuki S, Hashii Y, Yoshida H, Takizawa S, Sato E, Tokimasa S, Ohta H, Ozono K. Antifungal prophylaxis with micafungin in patients treated for childhood cancer. Pediatr Blood Cancer. 2009;53:605-9.